Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Share-based Compensation (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Share-based Compensation for 6 consecutive years, with $9.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 243.76% to $9.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $32.2 million, a 251.96% increase, with the full-year FY2025 number at $32.2 million, up 251.96% from a year prior.
  • Share-based Compensation was $9.8 million for Q4 2025 at GeneDx Holdings, down from $10.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $165.0 million in Q1 2021 to a low of -$912000.0 in Q4 2023.
  • A 5-year average of $15.1 million and a median of $3.4 million in 2024 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 4477.84% in 2022, then plummeted 1039.58% in 2024.
  • GeneDx Holdings' Share-based Compensation stood at $37.0 million in 2021, then crashed by 98.86% to $422000.0 in 2022, then crashed by 316.11% to -$912000.0 in 2023, then skyrocketed by 411.95% to $2.8 million in 2024, then skyrocketed by 243.76% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Share-based Compensation are $9.8 million (Q4 2025), $10.6 million (Q3 2025), and $7.8 million (Q2 2025).